;PMID: 2684256 ;source_file_1416.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..35] = [t:0..35] ;1)sentence:[e:40..136] = [t:40..136] ;2)section:[e:140..171] = [t:140..171] ;3)section:[e:175..273] = [t:175..273] ;4)sentence:[e:277..429] = [t:277..429] ;5)sentence:[e:431..568] = [t:431..568] ;6)sentence:[e:569..780] = [t:569..780] ;7)sentence:[e:781..909] = [t:781..909] ;8)sentence:[e:910..1144] = [t:910..1144] ;9)section:[e:1148..1192] = [t:1148..1192] ;section 0 Span:0..35 ;Br J Haematol 1989 Oct;73(2):165-7 (SEC (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..13] Haematol) (CD:[15..19] 1989) (-LRB-:[20..27] Oct;73-LRB-) (CD:[27..28] 2) (-RRB-:[28..29] -RRB-) (CD:[29..33] :165) (HYPH:[33..34] -) (CD:[34..35] 7))) ;sentence 1 Span:40..136 ;Co-incident N and K ras gene mutations in a case of AML, restricted to ;differing cell lineages. ;[52..53]...[60..63]:gene-rna:"N"..."ras" ;[58..63]:gene-rna:"K ras" ;[92..95]:malignancy:"AML" (SENT (NP-HLN (NP (NP (ADJP (AFX:[40..42] Co) (HYPH:[42..43] -) (JJ:[43..51] incident)) (NML (NML (NML (NN:[52..53] N) (NML-2 (-NONE-:[53..53] *P*))) (NML-1 (-NONE-:[53..53] *P*))) (CC:[54..57] and) (NML (NML (NN:[58..59] K) (NML-2 (NN:[60..63] ras))) (NML-1 (NN:[64..68] gene) (NNS:[69..78] mutations))))) (PP (IN:[79..81] in) (NP (NP (DT:[82..83] a) (NN:[84..88] case)) (PP (IN:[89..91] of) (NP (NN:[92..95] AML)))))) (,:[95..96] ,) (VP (VBN:[97..107] restricted) (NP (-NONE-:[107..107] *)) (PP (TO:[108..110] to) (NP (VBG:[111..120] differing) (NN:[122..126] cell) (NNS:[127..135] lineages)))) (.:[135..136] .))) ;section 2 Span:140..171 ;Hiorns LR, Cotter FE, Young BD. (SEC (FRAG (NNP:[140..146] Hiorns) (NNP:[147..149] LR) (,:[149..150] ,) (NNP:[151..157] Cotter) (NNP:[158..160] FE) (,:[160..161] ,) (NNP:[162..167] Young) (NNP:[168..171] BD.))) ;section 3 Span:175..273 ;Imperial Cancer Research Fund, Department of Medical Oncology, St ;Bartholomew's Hospital, London. (SEC (FRAG (NNP:[175..183] Imperial) (NNP:[184..190] Cancer) (NNP:[191..199] Research) (NNP:[200..204] Fund) (,:[204..205] ,) (NNP:[206..216] Department) (IN:[217..219] of) (NNP:[220..227] Medical) (NNP:[228..236] Oncology) (,:[236..237] ,) (NNP:[238..240] St) (NNP:[241..252] Bartholomew) (POS:[252..254] 's) (NN:[256..264] Hospital) (,:[264..265] ,) (NNP:[266..272] London) (.:[272..273] .))) ;sentence 4 Span:277..429 ;Peripheral blood from a patient with acute myeloid leukaemia (AML) of M5 FAB ;classification, was shown to have mutations to both the N and K ras genes. ;[314..369]:malignancy:"acute myeloid leukaemia (AML) of M5 FAB ;classification" ;[339..342]:malignancy:"AML" ;[411..412]...[419..422]:gene-rna:"N"..."ras" ;[417..422]:gene-rna:"K ras" (SENT (S (NP-SBJ-3 (NP (JJ:[277..287] Peripheral) (NN:[288..293] blood)) (PP (IN:[294..298] from) (NP (NP (DT:[299..300] a) (NN:[301..308] patient)) (PP (IN:[309..313] with) (NP (NP (NP (JJ:[314..319] acute) (JJ:[320..327] myeloid) (NN:[328..337] leukaemia)) (NP (-LRB-:[338..339] -LRB-) (NN:[339..342] AML) (-RRB-:[342..343] -RRB-))) (PP (IN:[344..346] of) (NP (NML (NN:[347..349] M5) (NN:[350..353] FAB)) (NN:[355..369] classification)))))))) (,:[369..370] ,) (VP (VBD:[371..374] was) (VP (VBN:[375..380] shown) (S (NP-SBJ-3 (-NONE-:[380..380] *)) (VP (TO:[381..383] to) (VP (VB:[384..388] have) (NP (NP (NNS:[389..398] mutations)) (PP (TO:[399..401] to) (NP (CC:[402..406] both) (DT:[407..410] the) (NML (NML (NML (NN:[411..412] N) (NML-1 (-NONE-:[412..412] *P*))) (NML-2 (-NONE-:[412..412] *P*))) (CC:[413..416] and) (NML (NML (NN:[417..418] K) (NML-1 (NN:[419..422] ras))) (NML-2 (NNS:[423..428] genes)))))))))))) (.:[428..429] .))) ;sentence 5 Span:431..568 ;Leucophoresed blood was separated on a discontinuous Percoll density gradient ;to provide fractions enriched for different cell lineages. (SENT (S (NP-SBJ-1 (VBN:[431..444] Leucophoresed) (NN:[445..450] blood)) (VP (VBD:[451..454] was) (VP (VBN:[455..464] separated) (NP-1 (-NONE-:[464..464] *)) (PP-MNR (IN:[465..467] on) (NP (DT:[468..469] a) (JJ:[470..483] discontinuous) (NNP:[484..491] Percoll) (NN:[492..499] density) (NN:[500..508] gradient))) (S-PRP (NP-SBJ (-NONE-:[508..508] *)) (VP (TO:[509..511] to) (VP (VB:[513..520] provide) (NP (NP (NNS:[521..530] fractions)) (VP (VBN:[531..539] enriched) (NP (-NONE-:[539..539] *)) (PP (IN:[540..543] for) (NP (JJ:[544..553] different) (NN:[554..558] cell) (NNS:[559..567] lineages)))))))))) (.:[567..568] .))) ;sentence 6 Span:569..780 ;DNA extracted from these fractions was amplified using the polymerase chain ;reaction (PCR) technique, and hybridized with oligonucleotide probes ;specific for the single base mutations previously demonstrated. ;[629..639]:gene-protein:"polymerase" ;[733..754]:variation-type:"single base mutations" (SENT (S (NP-SBJ-1 (NP (NN:[569..572] DNA)) (VP (VBN:[573..582] extracted) (NP (-NONE-:[582..582] *)) (PP (IN:[583..587] from) (NP (DT:[588..593] these) (NNS:[595..604] fractions))))) (VP (VBD:[605..608] was) (VP (VP (VBN:[609..618] amplified) (NP-1 (-NONE-:[618..618] *)) (S-MNR (NP-SBJ (-NONE-:[618..618] *)) (VP (VBG:[619..624] using) (NP (DT:[625..628] the) (NML (NML (NN:[629..639] polymerase) (NN:[640..645] chain) (NN:[646..654] reaction)) (NML (-LRB-:[655..656] -LRB-) (NN:[656..659] PCR) (-RRB-:[659..660] -RRB-))) (NN:[661..670] technique))))) (,:[670..671] ,) (CC:[672..675] and) (VP (VBN:[677..687] hybridized) (NP-1 (-NONE-:[687..687] *)) (PP (IN:[688..692] with) (NP (NP (NN:[693..708] oligonucleotide) (NNS:[709..715] probes)) (ADJP (JJ:[716..724] specific) (PP (IN:[725..728] for) (NP (NP (DT:[729..732] the) (NML (JJ:[733..739] single) (NN:[740..744] base)) (NNS:[745..754] mutations)) (VP (RB:[756..766] previously) (VBN:[767..779] demonstrated) (NP (-NONE-:[779..779] *))))))))))) (.:[779..780] .))) ;sentence 7 Span:781..909 ;The N-ras mutation was shown to be restricted to the blast and monocytic ;cell fractions, concordant with the FAB subtype of M5. ;[785..790]:gene-rna:"N-ras" (SENT (S (NP-SBJ-2 (DT:[781..784] The) (NN:[785..790] N-ras) (NN:[791..799] mutation)) (VP (VBD:[800..803] was) (VP (VBN:[804..809] shown) (S (NP-SBJ-2 (-NONE-:[809..809] *)) (VP (TO:[810..812] to) (VP (VB:[813..815] be) (ADJP-PRD (JJ:[816..826] restricted) (PP (TO:[827..829] to) (NP (DT:[830..833] the) (NML (NML (NN:[835..840] blast) (NML-1 (-NONE-:[840..840] *P*))) (CC:[841..844] and) (NML (JJ:[845..854] monocytic) (NML-1 (NN:[855..859] cell) (NNS:[860..869] fractions)))))))))) (,:[869..870] ,) (S-ADV (NP-SBJ (-NONE-:[870..870] *)) (ADJP-PRD (JJ:[871..881] concordant) (PP (IN:[882..886] with) (NP (NP (DT:[887..890] the) (NN:[891..894] FAB) (NN:[895..902] subtype)) (PP (IN:[903..905] of) (NP (NN:[906..908] M5))))))))) (.:[908..909] .))) ;sentence 8 Span:910..1144 ;The K-ras mutation, however, was present in all fractions, suggesting it had ; occurred in a multi-potential stem cell representing an earlier stage in the ; generation of the leukaemia, or possibly an incidental background ;phenomenon. ;[915..920]:gene-rna:"K-ras" ;[1085..1094]:malignancy:"leukaemia" (SENT (S (NP-SBJ (DT:[910..913] The) (NN:[915..920] K-ras) (NN:[921..929] mutation)) (,:[929..930] ,) (ADVP (RB:[931..938] however)) (,:[938..939] ,) (VP (VBD:[940..943] was) (ADJP-PRD (JJ:[944..951] present)) (PP-LOC (IN:[952..954] in) (NP (DT:[955..958] all) (NNS:[959..968] fractions))) (,:[968..969] ,) (S-ADV (NP-SBJ (-NONE-:[969..969] *)) (VP (VBG:[970..980] suggesting) (SBAR (-NONE-:[980..980] 0) (S (NP-SBJ (PRP:[981..983] it)) (VP (VBD:[984..987] had) (VP (VBN:[989..997] occurred) (PP (IN:[998..1000] in) (NP (NP (DT:[1001..1002] a) (ADJP (AFX:[1003..1008] multi) (HYPH:[1008..1009] -) (NN:[1009..1018] potential)) (NN:[1019..1023] stem) (NN:[1024..1028] cell)) (VP (VBG:[1029..1041] representing) (NP (NP (NP (DT:[1042..1044] an) (JJR:[1045..1052] earlier) (NN:[1053..1058] stage)) (PP (IN:[1059..1061] in) (NP (NP (DT:[1062..1065] the) (NN:[1067..1077] generation)) (PP (IN:[1078..1080] of) (NP (DT:[1081..1084] the) (NN:[1085..1094] leukaemia)))))) (,:[1094..1095] ,) (CC:[1096..1098] or) (NP (ADVP (RB:[1099..1107] possibly)) (DT:[1108..1110] an) (JJ:[1111..1121] incidental) (NN:[1122..1132] background) (NN:[1133..1143] phenomenon))))))))))))) (.:[1143..1144] .))) ;section 9 Span:1148..1192 ;PMID: 2684256 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1148..1152] PMID) (::[1152..1153] :) (CD:[1154..1161] 2684256) (IN:[1162..1163] -LSB-) (NNP:[1163..1169] PubMed) (HYPH:[1170..1171] -) (JJ:[1172..1179] indexed) (IN:[1180..1183] for) (NNP:[1184..1192] MEDLINE-RSB-)))